The Short Answer
As of April 2026, Ozempic (semaglutide) is officially available and CDSCO-approved in India for Type 2 Diabetes. Furthermore, the landscape for weight loss has changed drastically with the launch of domestic semaglutide generics by major Indian pharma companies, some of which carry official indications for chronic weight management.
Current Availability in India
Official Brand Access
Novo Nordisk officially launched Ozempic in India in December 2025. It is available at major hospitals and authorized pharmacies with a valid prescription from an endocrinologist.The Generic Revolution (March 2026)
The core patent for semaglutide expired in March 2026, leading to a "Day 1" launch of several affordable Indian versions:- Dr. Reddy's: Launched Obeda™ (injectable).
- Zydus Lifesciences: Launched Semaglyn™, approved for both Type 2 Diabetes and obesity.
- Alkem & Sun Pharma: Launched various brands including Noveltreat™ and Semasize™.
2026 Pricing in India (INR)
Prices have dropped by over 60% compared to previous import costs.
| Product Type | Brand Example | Monthly Price (Approx.) | |---|---|---| | Official Ozempic | Ozempic (Novo Nordisk) | ₹8,800 – ₹11,200 | | Premium Generics | Obeda™ / Semaglyn™ | ₹3,000 – ₹4,500 | | Budget Generics | Semasize™ / Noveltreat™ | ₹1,200 – ₹2,000 | | Oral Semaglutide | Rybelsus (Official) | ₹3,000 – ₹5,000 |
Regulatory Status for Weight Loss
While Ozempic is primarily indicated for diabetes, the CDSCO has recently granted manufacturing and marketing permissions for specific generic semaglutide injections (such as those from Zydus and Alkem) specifically for chronic weight management in adults with a BMI ≥ 30 (or ≥ 27 with comorbidities).Our Recommendation
- Consult an Expert: Ensure you see a registered endocrinologist; the CDSCO specifically mandates that these drugs be prescribed by specialists.
- Prioritize Approved Generics: There is no longer a need for risky "grey market" imports. Domestic generics are regulated, temperature-controlled, and significantly cheaper.
- Monitor Health: Clinical trials in India emphasize screening for pancreatic history and regular monitoring of renal and hepatic functions.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified physician before starting, changing, or stopping any medication.